Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine versus SSRIs in elderly patients with major depression
2018-001444-66Phase 3Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vortioxetine, sertraline, citalopram, escitalopram, fluoxetine and 2 more in major depressive disorder (MDD) (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Withdrawal due to adverse events. Started Dec 2020; status: completed.
02
Drugs
vortioxetinesertralinecitalopramescitalopramfluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-001444-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001444-66.